AIA Group Ltd raised its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) by 36.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,924 shares of the biopharmaceutical company’s stock after purchasing an additional 1,039 shares during the quarter. AIA Group Ltd’s holdings in Alnylam Pharmaceuticals were worth $785,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors have also recently made changes to their positions in ALNY. Allworth Financial LP increased its holdings in Alnylam Pharmaceuticals by 708.7% during the third quarter. Allworth Financial LP now owns 186 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 163 shares during the last quarter. SeaCrest Wealth Management LLC bought a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter worth approximately $44,000. SCHRODERS IS Ltd purchased a new position in Alnylam Pharmaceuticals in the second quarter valued at approximately $74,000. Alta Advisers Ltd bought a new position in Alnylam Pharmaceuticals during the third quarter valued at $80,000. Finally, 1832 Asset Management L.P. purchased a new stake in Alnylam Pharmaceuticals in the first quarter worth $88,000.
Analyst Ratings Changes
Several brokerages recently weighed in on ALNY. JPMorgan Chase & Co. decreased their price objective on Alnylam Pharmaceuticals from $204.00 to $200.00 and set a “neutral” rating for the company in a report on Monday, October 24th. StockNews.com started coverage on shares of Alnylam Pharmaceuticals in a research note on Wednesday, October 12th. They issued a “hold” rating for the company. Barclays cut their price objective on shares of Alnylam Pharmaceuticals from $240.00 to $236.00 and set an “overweight” rating for the company in a report on Friday, October 28th. Piper Sandler boosted their target price on shares of Alnylam Pharmaceuticals from $226.00 to $253.00 and gave the company an “overweight” rating in a report on Friday, December 16th. Finally, Canaccord Genuity Group began coverage on Alnylam Pharmaceuticals in a report on Wednesday, January 18th. They issued a “buy” rating and a $310.00 price target for the company. Seven equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $239.84.
Alnylam Pharmaceuticals Stock Performance
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) last issued its quarterly earnings data on Thursday, October 27th. The biopharmaceutical company reported ($3.32) EPS for the quarter, missing the consensus estimate of ($1.86) by ($1.46). Alnylam Pharmaceuticals had a negative return on equity of 430.74% and a negative net margin of 123.02%. The business had revenue of $264.31 million for the quarter, compared to analysts’ expectations of $291.81 million. During the same period in the previous year, the firm posted ($1.72) EPS. The firm’s revenue for the quarter was up 40.9% compared to the same quarter last year. As a group, sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -9.64 EPS for the current fiscal year.
Alnylam Pharmaceuticals Profile
Alnylam Pharmaceuticals, Inc is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. Its products include ONPATTRO, GIVLAARI, and OXLUMO. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R.
- Get a free copy of the StockNews.com research report on Alnylam Pharmaceuticals (ALNY)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- When Will Crane Holdings Take Flight?
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.